Cel Sci (CVM) Common Equity (2010 - 2026)
Cel Sci (CVM) posted Common Equity of $6.9 million for Q1 2026, down 38.28% sequentially from $11.1 million in Q4 2025, and down 14.04% YoY from $8.0 million in Q1 2025.
Cel Sci (CVM) Common Equity (2010 - 2026) Analysis & Trends
Cel Sci has reported Common Equity for 17 years, with the latest figure at $6.9 million in Q1 2026.
- Quarterly Common Equity fell 14.04% year-over-year to $6.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.9 million (down 14.04% YoY) and the FY2025 annual result came in at $16.0 million, up 24.01% from the prior year.
- Common Equity declined to $6.9 million in Q1 2026 per CVM's latest filing, from $11.1 million in the prior quarter.
- Over five years, Common Equity peaked at $45.1 million in Q1 2022 and troughed at $6.9 million in Q1 2026.
- A 5-year average of $17.6 million and a median of $13.2 million in 2023 frame the typical range for Common Equity.
- The sharpest annual moves came in 2022 and 2023: Common Equity jumped 53.85% in 2022, then sank 61.81% in 2023.
- Over 5 years, Common Equity stood at $26.6 million in 2022, then slumped by 52.43% to $12.7 million in 2023, then decreased by 10.61% to $11.3 million in 2024, then declined by 1.5% to $11.1 million in 2025, then slumped by 38.28% to $6.9 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $6.9 million, $11.1 million, and $16.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.79 Bn |
| 10 | Cel Sci | 2.12 Mn | -4.42 Mn | - | 10.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.87 Mn |
| Dec 31, 2025 | 11.14 Mn |
| Sep 30, 2025 | 15.96 Mn |
| Jun 30, 2025 | 7.02 Mn |
| Mar 31, 2025 | 8.00 Mn |
| Dec 31, 2024 | 11.31 Mn |
| Sep 30, 2024 | 12.87 Mn |
| Jun 30, 2024 | 8.47 Mn |
| Mar 31, 2024 | 14.30 Mn |
| Dec 31, 2023 | 12.65 Mn |
| Sep 30, 2023 | 13.21 Mn |
| Jun 30, 2023 | 14.79 Mn |
| Mar 31, 2023 | 20.15 Mn |
| Dec 31, 2022 | 26.59 Mn |
| Sep 30, 2022 | 32.16 Mn |
| Jun 30, 2022 | 38.73 Mn |
| Mar 31, 2022 | 45.13 Mn |
| Dec 31, 2021 | 51.35 Mn |
| Sep 30, 2021 | 56.53 Mn |
| Jun 30, 2021 | 59.79 Mn |